

ARRAY BIOPHARMA INC  
Form 8-K  
September 04, 2009

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

## FORM 8-K

### CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 3, 2009**

### **Array BioPharma Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other  
Jurisdiction of  
Incorporation)

**000-31979**  
(Commission  
File Number)

**84-1460811**  
(IRS Employer  
Identification No.)

**3200 Walnut Street, Boulder, Colorado**  
(Address of Principal Executive Offices)

**80301**  
(Zip Code)

Registrant's telephone number, including area code: **(303) 381-6600**

(Former Name or Former Address, if Changed Since Last Report)

## Edgar Filing: ARRAY BIOPHARMA INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events**

On September 3, 2009, Array BioPharma Inc. issued a press release announcing top-line results from rheumatoid arthritis phase 2 trial. The full text of this press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

- 99.1 Press release dated September 3, 2009 entitled Array BioPharma Announces Top-Line Results From Rheumatoid Arthritis Phase 2 Trial.
- 99.2 Website slides dated September 3, 2009 entitled ARRY-162-201: A 12-week, Phase 2, Randomized, Double-blind, Multicenter, Placebo Controlled Study to Investigate the Safety, Pharmacokinetics and Efficacy of ARRY-162, Administered Orally Daily in Patients with Active Rheumatoid Arthritis Incompletely Responsive to Methotrexate-Top-Line Results

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARRAY BIOPHARMA INC.

Date: September 3, 2009

By:

/s/ R. Michael Carruthers  
R. Michael Carruthers  
Chief Financial Officer

**EXHIBIT INDEX**

**Exhibit No.**

- 99.1 Press release dated September 3, 2009 entitled Array BioPharma Announces Top Line Results From Rheumatoid Arthritis Phase 2 Trial.
- 99.2 Website slides dated September 3, 2009 entitled ARRY-162-201: A 12-week, Phase 2, Randomized, Double-blind, Multicenter, Placebo Controlled Study to Investigate the Safety, Pharmacokinetics and Efficacy of ARRY-162, Administered Orally Daily in Patients with Active Rheumatoid Arthritis Incompletely Responsive to Methotrexate-Top-Line Results